Pivekimab sunirine and the evolving treatment of blastic plasmacytoid dendritic cell neoplasm.

Pivekimab sunirine, an anti-CD123 antibody-drug conjugate, was approved by the FDA on May 27, 2026, for adults with blastic plasmacytoid dendritic cell neoplasm based on CADENZA.

• Why it matters: BPDCN is rare and aggressive, with leukemic blasts, frequent skin involvement, and high CD123 expression, creating a need for targeted therapies and clear guidance on evolving treatment options.
• What they did: The review summarizes pivekimab sunirine’s mechanism, clinical efficacy, and toxicity, and places it within the broader treatment landscape for BPDCN and AML, referencing CADENZA for the approval basis.
• The result: The approval supports incorporating pivekimab sunirine into adult BPDCN care and frames how its benefits and risks may fit alongside other emerging approaches for BPDCN and AML.

AI summary of the abstract · may contain errors · not medical advice · read the paper.